Its expert medical care, tailored to your life, right from the privacy of your own home
Combination Approaches Future treatments might combine incretin agonists with other weight loss mechanisms like metabolism boosters, appetite suppressants working through non-incretin pathways, or fat absorption inhibitors
13 Because of the lower risk of the patients, a much longer trial (median 5.4 years) was required to achieve sufficient cardiovascular endpoints than in the previous CVOTs with GLP-1RA (median 1.63.6 years)
Here's the real deal on GLP-1s and why it matters for your midlife metabolism, how prescription medications stack up against supplements, and whether these over-the-counter options can actually help with blood sugar, appetite, weight management, or side effects
As this technology continues to develop, it is critical to expand access so that all patients for whom these medications are a good fit can benefit from personalized treatment for obesity
2024 Feb;46(2):e64-e72
